Sign In

David Cruz

Entrepreneur - Green Nanotechnology - Nanomedicine - Founder at SynCell Biotechnology - Founder at Nanolyx - National Nonprofit CFO -

Professional Background

David Medina Cruz, PhD, is a distinguished scientist whose career encompasses a wealth of research and innovation in the fields of Chemical Engineering and Nanotechnology. With a focus on Green Nanotechnology, he has dedicated his research to tackling significant global health challenges, particularly those linked to antimicrobial resistance and chemotherapy resistance. His impressive tenure in various laboratories across disciplines, including Biological Sciences, Physics, and Chemistry, solidifies his expertise in the development of innovative solutions aimed at improving public health outcomes.

Currently, David serves as a scientist at a leading gene therapy company, where he spearheads the gene delivery department, providing critical insights and methods to enhance therapeutic efficacy. His commitment to sustainable and environmentally friendly practices is further showcased through his entrepreneurial endeavors, founding The Green Chemistry Lab and SynCell Biotechnology, which focus on leveraging nanotechnology for therapeutic applications. He emphasizes a hands-on approach, often stating, "Point me the element, and I will give you the particle," showcasing his confidence and versatility in working with various materials on both nano and microscale levels.

Education and Achievements

David's educational achievements are as extensive as his professional endeavors. He obtained his Doctor of Philosophy in Chemical Engineering from Northeastern University, complemented by a MicroMaster in Design Thinking from the Rochester Institute of Technology. His foray into entrepreneurship was furthered through the Start Smart Class for Entrepreneurs at the Massachusetts Institute of Technology, where he honed his business acumen and financial management expertise through coursework at Cornell University. David's dedication to lifelong learning is evident in his diverse set of qualifications, including a Graduate Certificate in Nanomedicine and a Master’s Degree in Nanoscience from prestigious institutions such as Universitat Rovira i Virgili and Universidad de Castilla-La Mancha.

Throughout his career, David has also embraced leadership roles, serving as the Chief Financial Officer and Treasurer at the national scientific nonprofit organization ECUSA, demonstrating his financial savvy and commitment to supporting the scientific community. Furthermore, his mentorship roles at Nucleate and Solve - MIT exemplify his dedication to guiding the next generation of scientists and entrepreneurs in achieving their goals.

Achievements

Dr. Medina Cruz's remarkable contributions extend beyond research and into the startup ecosystem. As co-founder and advisor at Nanolyx Inc., he helped establish a materials science startup specializing in antimicrobial nanocoatings. His ability to navigate the intersection of science and entrepreneurship has positioned him as a thought leader in the biotechnology field. In addition, his work with SynCell Biotechnology and Novaurum Biosciences highlights his innovative approach to developing nanoscale therapeutic solutions, particularly using selenium nanoparticles sourced from pathogenic bacteria.

David’s history of collaboration and mentorship underlines his desire to enrich the science community. As a board member and leader within various scientific organizations, he has consistently worked toward fostering a culture that promotes growth and excellence. His capabilities in management and finance, coupled with his scientific prowess, make him a valuable asset to any organization he is part of, as he continues to push the boundaries of what is possible in nanotechnology and biomedical research.

In summary, David Medina Cruz, PhD, exemplifies the qualities of a leading scientist, entrepreneur, and mentor. His dedication to environmentally responsible scientific practices and superior educational foundation fuels his commitment to improving healthcare outcomes. With his wealth of experience and passion for science, combined with his innovation in industry practices, David is poised to make an even greater impact on the world of biotechnology and nanomedicine in the years to come.

Highlights

Apr 30 · linkedin

Endosomal escape, and the potential for reducing inflammation in LNP-based therapies: a possibility that might become a reality sooner than expected

Despite their success of LNPs in the clinic, a significant hurdle remains: LNPs are associated with severe, sometimes exacerbated pre-existing inflammation, an unintended consequence which has prompted a deeper exploration into the mechanisms of LNP-induced inflammation and the pursuit of innovative solutions to mitigate these effects.

Through what I would call a "meticulous process of structure-function screening" of lipids and analyses of signaling pathways, a team of researchers have begun to unravel the complexities behind the inflammation caused by LNPs.

A key discovery is the dual role of the LNPs' ability to escape endosomes. While essential for effective RNA expression, this feature also directly triggers inflammation by damaging endosomal membranes. The large, irreparable holes created are recognized by cytosolic proteins known as galectins, which bind to sugars on the damaged endosomal membranes and catalyze downstream inflammatory responses.

Their research reveals two promising strategies to circumvent this inflammatory response:

1- Inhibiting galectins effectively abrogates LNP-associated inflammation, both in vitro and in vivo. This approach prevents the recognition of extensive endosomal damage, thus blocking the inflammatory cascade at its origin.

2- Secondly, the team has developed rapidly biodegradable ionizable lipids that create smaller, reparable holes in endosomes. These minor disruptions are manageable by the endosomal sorting complex required for transport (ESCRT) pathway, allowing for high mRNA expression without significant inflammatory reactions.

These findings not only enhance our understanding of LNP-induced inflammation but also offer viable paths forward. By either inhibiting galectin activity or employing biodegradable ionizable lipids, we can design LNPs that minimize inflammation while maintaining their efficacy in mRNA delivery. Both approaches have shown compatibility with therapeutic mRNAs that reduce inflammation in disease models, contrasting sharply with traditional LNPs that exacerbate inflammatory conditions.

Learn more here: https://lnkd.in/ew3rzNF3

#Nanomedicine #RNAtherapy #InflammationControl #InnovativeResearch #endosomalescape #nanotech #lipidnanoparticles #lipids #nanomaterials

Apr 8 · linkedin

Isolating the formation kinetics of peptide-based miRNA nanoparticles for better targeted nano therapeutics!

In the quest to harness the power of microRNA (miRNA) for cancer treatment, scientists face significant challenges, including the broad size distribution and poor long-term colloidal stability of miRNA-carrying nanoparticles. Indeed, these obstacles have delayed the clinical application of such nanoparticles, particularly those formed through polyelectrolyte complexation. However, a new study has set a new precedent.

Leveraging the art of peptide design and a "cutting-edge" technique known as optimized flash nanocomplexation (FNC), researchers have crafted uniform peptide-based miRNA particles that stand out for their exceptional stability and potent anticancer activity, both in vitro and in vivo. The secret to their success? The strategic modulation of lysine-based charge within small intrinsically disordered peptides, essential for complexing miRNA and achieving stable colloidal solutions.

FNC emerges as a game-changer, isolating kinetic steps in particle formation, thus allowing for the production of particles with discrete sizes in a manner that is not only highly reproducible but also scalable. This advancement paves the way for seamless pre-clinical studies and marks the first instance, to the authors' knowledge, of using FNC for preparing miRNA and peptide polyelectrolyte complexes.

The encapsulation of these particles within an injectable hydrogel matrix revolutionizes their in vivo delivery. A one-time syringe injection of a gel laden with particles composed of miRNA-215-5p and the peptide PKM1 significantly curtails tumor progression in a xenograft model of mesothelioma.

This study not only shows a clearer path toward overcoming longstanding barriers in miRNA therapeutic delivery but also exemplifies the potential of peptide-based nanoparticles in advancing cancer treatment.

Learn more here: https://lnkd.in/eMBc-JzP

#CancerTherapy #miRNA #Nanotechnology #InnovativeResearch #nanotech #nanomaterials #nanotherapeutics #genedelivery #delivery

Related Questions

How did David Medina Cruz develop his expertise in Green Nanotechnology?
What are the key impacts of David's research on antimicrobial resistance?
In what ways has David contributed to entrepreneurship in biotechnology?
How has David's educational background influenced his professional journey?
What initiatives has David taken to mentor young scientists and entrepreneurs?
How does David's work at Alltrna align with his research interests?
What challenges has David faced in his entrepreneurial ventures, and how has he overcome them?
What innovations in gene delivery has David implemented in his current role?
How does David approach the sustainable synthesis of nanomaterials?
What future projects does David Medina Cruz envision in the field of nanotechnology?
David Cruz
Add to my network

Location

Boston, Massachusetts, United States